GTHX
- G1 Therapeutics, Inc.
()
Overview
Company Summary
G1 Therapeutics, Inc. (GTHX) is a pharmaceutical company focused on the discovery, development, and commercialization of novel therapies for people suffering from cancer. Their primary goal is to develop innovative drugs that target specific proteins involved in the regulation of the cell cycle for treating various forms of cancer.
G1 Therapeutics specializes in developing small molecule inhibitors, which are drugs designed to disrupt the processes that allow cancer cells to grow and divide uncontrollably. Their research is centered around targeting two specific proteins, known as cyclin-dependent kinases (CDKs) 4 and 6, which play a critical role in regulating the cell cycle.
By inhibiting CDK4/6, G1 Therapeutics aims to stop cancer cells from proliferating and spreading. Their investigational drugs are being studied for their potential in treating a range of solid tumor cancers, including lung, breast, and ovarian cancers.
Moreover, G1 Therapeutics also focuses on developing drugs that can protect healthy cells from the toxicity induced by chemotherapy and radiation therapy. These therapies often lead to undesirable side effects, and the company aims to attenuate or prevent these toxic effects by developing drugs that selectively protect healthy cells without compromising the efficacy of treatment.
In addition to their drug development efforts, G1 Therapeutics also engages in preclinical and clinical research, collaborating with academic institutions, clinical centers, and other pharmaceutical companies to advance their pipeline of potential cancer therapies.
Overall, G1 Therapeutics is dedicated to improving patient outcomes by targeting specific molecular pathways involved in cancer growth and providing innovative therapeutic solutions to address unmet medical needs in various cancer indications.